Human Challenge Studies for Cholera
- PMID: 35377003
- DOI: 10.1007/82_2022_258
Human Challenge Studies for Cholera
Abstract
The human challenge model permits an estimate of the vaccine protection against moderate and severe cholera. It eliminates the difficulty in setting up a vaccine study in endemic area including uncertainties about the incidence of cholera and the logistic arrangements for capturing those who do/do not become ill. Valuable information from small groups of subjects can be obtained in a short period. Under proper precautions and study design, the challenge model is safe and efficient. Although the model has evolved since it was introduced over 50 years ago, it has been used extensively to test vaccine efficacy. Vaccine licensure has resulted from data obtained using the human challenge model. In addition, the model has been used to: (1) Establish and validate a standardized inoculum, (2) Identify immune markers and immune responses, (3) Determine natural immunity (in re-challenge studies), (4) Identify the role of the gastric acid barrier in preventing cholera infection, (5) Show homologous and heterologous infection-derived immunity, and (6) Test the efficacy of anti-diarrheal/anti-secretory small molecules. The aim of this chapter is to present an overview on the state of the art for human challenge models used to study cholera and new medical interventions against it.
Keywords: Cholera; Licensure; Protective efficacy; Safety; Vaccine.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Similar articles
-
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.Infect Immun. 1999 Dec;67(12):6341-5. doi: 10.1128/IAI.67.12.6341-6345.1999. Infect Immun. 1999. PMID: 10569747 Free PMC article. Clinical Trial.
-
The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.Infect Immun. 2005 May;73(5):3018-24. doi: 10.1128/IAI.73.5.3018-3024.2005. Infect Immun. 2005. PMID: 15845509 Free PMC article. Clinical Trial.
-
Oral immunization with a probiotic cholera vaccine induces broad protective immunity against Vibrio cholerae colonization and disease in mice.PLoS Negl Trop Dis. 2019 May 31;13(5):e0007417. doi: 10.1371/journal.pntd.0007417. eCollection 2019 May. PLoS Negl Trop Dis. 2019. PMID: 31150386 Free PMC article.
-
The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine.Microbiol Immunol. 2006;50(12):899-927. doi: 10.1111/j.1348-0421.2006.tb03866.x. Microbiol Immunol. 2006. PMID: 17179659 Review.
-
PaxVax CVD 103-HgR single-dose live oral cholera vaccine.Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Expert Rev Vaccines. 2017. PMID: 28165831 Review.
Cited by
-
Controlled human malaria infection: overview and potential application in the evaluation of transmission-blocking interventions in malaria-endemic areas.Malar J. 2025 Feb 1;24(1):33. doi: 10.1186/s12936-025-05277-x. Malar J. 2025. PMID: 39893367 Free PMC article. Review.
-
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.J Infect Dis. 2024 May 15;229(5):1498-1508. doi: 10.1093/infdis/jiad441. J Infect Dis. 2024. PMID: 38019956 Free PMC article. Clinical Trial.
-
The Challenge Non-Typhoidal Salmonella (CHANTS) Consortium: Development of a non-typhoidal Salmonella controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK.Wellcome Open Res. 2023 Sep 21;8:111. doi: 10.12688/wellcomeopenres.19012.2. eCollection 2023. Wellcome Open Res. 2023. PMID: 37808389 Free PMC article.
References
-
- Chen WH, Garza J, Choquette M, Hawkins J, Hoeper A, Bernstein DI, Cohen MB (2015) Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae. Clin Vaccine Immunol 22:129–135 - DOI - PubMed
-
- Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM (2016) Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin Infect Dis 62:1329–1335 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical